Observational studyThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2020
Statin Use and Risk of Cognitive Decline in the ADNI Cohort.
Observational study in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Threshold effects of insulin resistance on cognitive function in coronary heart disease: the non-linear diagnostic value of the triglyceride-glucose index.Frontiers in cardiovascular medicine · 2026Article
- Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations.Current cardiology reports · 2025Review
- A simple nomogram to predict the onset of dementia in mild cognitive impairment: A retrospective study.Journal of Alzheimer's disease : JAD · 2025Article
- Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Medication Exposure and Risk of Dementia and Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence.Current atherosclerosis reports · 2024Review
- Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study.Alzheimer's research & therapy · 2023Article
- The Effects of Statins on Cognitive Performance Are Mediated by Low-Density Lipoprotein, C-Reactive Protein, and Blood Glucose Concentrations.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Article
- New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.Acta pharmacologica Sinica · 2021Review
- Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.Current urology reports · 2020Review
- Neuro-cognitive profile of adult statin users at a large tertiary care hospital in Delhi, India.JRSM cardiovascular diseaseArticle
- Is the use of high-intensity atorvastatin associated with memory impairment?Indian heart journalObservational
- Adherence to Statins Use and Risk of Dementia among Patients with Diabetes and Comorbid Hyperlipidemia.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo investigate associations between statin use and cognitive change, as well as diagnostic conversion, in individuals with cognitively normal (CN) status, mild cognitive impairment (MCI), and dementia due to Alzheimer disease (AD-dementia).
methodsA multicenter cohort study with 1629 adults 48 to 91 years old with CN status, early MCI (EMCI), late MCI (LMCI), or AD-dementia at baseline followed prospectively for 24 months. Statin use was assessed at baseline, and cognition was measured over time with a composite memory score, a composite executive function score, and a global cognition score (Alzheimer's Disease Assessment Scale). Conversion to a more impaired diagnostic category was determined by clinician assessment. Repeated measures linear mixed-effects models were used to evaluate associations between statin use and change in cognition over time. Cox proportional hazards models were used to evaluate associations between statin use and time to diagnostic conversion. All models were stratified by baseline diagnostic group.
resultsStatin use was not associated with change in cognitive measures for CN, LMCI, or AD-dementia participants. Among EMCI participants, statin use was associated with a significantly slower rate of decline on the memory composite, but no other cognitive measure. Statin use was not associated with time to conversion for any diagnostic group.
conclusionsThis study did not support an association between statin use and diagnostic conversion but suggested a possible association between statin use and cognitive change in EMCI. Additional randomized clinical trials of statins may be warranted in the prodromal EMCI stage of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.